Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK^® + rituximab for the treatment of B-cell driven diseases in a community setting